Sun Shengbo, Yang Zhengyang, Yao Hongwei, Zhang Zhongtao
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, China; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, China.
Trends Cancer. 2025 Feb;11(2):84-87. doi: 10.1016/j.trecan.2024.10.002. Epub 2024 Oct 24.
Anti-programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) immunotherapy has shown promising results in cancer treatment, improving clinical outcomes and prolonging patient survival. However, most patients exhibit low response rates to PD-1/PD-L1 blockade, highlighting the urgent need for new enhancers. Increasing data now demonstrate that inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine proteinase, can enhance the antitumor efficacy of anti-PD-1/PD-L1 immunotherapy.
抗程序性细胞死亡蛋白1（PD-1）/PD-1配体1（PD-L1）免疫疗法在癌症治疗中已显示出有前景的结果，改善了临床结局并延长了患者生存期。然而，大多数患者对PD-1/PD-L1阻断的反应率较低，这凸显了对新型增强剂的迫切需求。现在越来越多的数据表明，抑制丝氨酸蛋白酶前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）可以增强抗PD-1/PD-L1免疫疗法的抗肿瘤疗效。
